An editorial notes that even though the use of statins in cardiac surgery is likely to continue to generate interest and trials in an attempt to demonstrate other so-far unproven benefits, any use as nephroprotective agents in patients naive to statin treatment undergoing cardiac surgery should now be abandoned. The challenge of finding an adjuvant intervention capable of attenuating acute kidney injury during cardiac surgery, however, remains unmet.